The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Docetaxel + ramucirumab (DR) versus docetaxel + placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.
 
Yukio Hosomi
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Yakult Pharmaceutical (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly (Inst); Novartis (Inst); Takeda (Inst)
 
Kazuo Kasahara
Honoraria - Chugai Pharma; Lilly
Research Funding - AstraZeneca (Inst); Lilly (Inst); Pfizer (Inst)
 
Kazuhiko Yamada
Honoraria - Boehringer Ingelheim; Chugai Pharma; Pfizer; Taiho Pharmaceutical
Research Funding - Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Toshiaki Takahashi
Speakers' Bureau - AstraZeneca; Lilly; Ono Pharmaceutical
Research Funding - Lilly (Inst)
 
Kaoru Tanaka
No Relationships to Disclose
 
Toyoaki Hida
Honoraria - Chugai Pharma; Lilly
Research Funding - Chugai Pharma (Inst); Lilly (Inst)
 
Hiroshige Yoshioka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Lilly
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Lilly
Consulting or Advisory Role - Lilly
Research Funding - Lilly (Inst)
 
Koji Takeda
Honoraria - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Mochida Pharmaceutical Co. Ltd.; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst)
 
Makoto Nishio
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Chugai Pharma; Elekta; Lilly; Nicholas Piramal; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Hiroshi Sakai
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
 
Makoto Maemondo
Honoraria - Chugai Pharma; Lilly
Consulting or Advisory Role - Lilly
Research Funding - Chugai Pharma (Inst); Lilly (Inst)
 
Mitsuhiro Takenoyama
Speakers' Bureau - Chugai Pharma; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Hiroshi Nokihara
Honoraria - Boehringer Ingelheim; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Masumi Tatsumi
Employment - Lilly
 
Takashi Nakamura
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Sotaro Enatsu
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Tomohide Tamura
Honoraria - Astellas Pharma; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kazuhiko Nakagawa
Honoraria - Chugai Pharma; Lilly
Speakers' Bureau - Chugai Pharma; Lilly
Research Funding - Chugai Pharma (Inst)